221 related articles for article (PubMed ID: 25367164)
21. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
Findling RL; Landbloom RP; Mackle M; Pallozzi W; Braat S; Hundt C; Wamboldt MZ; Mathews M
J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):384-96. PubMed ID: 26091193
[TBL] [Abstract][Full Text] [Related]
22. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
Addington DE; Mohamed S; Rosenheck RA; Davis SM; Stroup TS; McEvoy JP; Swartz MS; Lieberman JA
J Clin Psychiatry; 2011 Jan; 72(1):75-80. PubMed ID: 20868641
[TBL] [Abstract][Full Text] [Related]
23. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
24. Dosing the antipsychotic medication olanzapine.
Nemeroff CB
J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
[TBL] [Abstract][Full Text] [Related]
25. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
Szegedi A; Verweij P; van Duijnhoven W; Mackle M; Cazorla P; Fennema H
J Clin Psychiatry; 2012 Dec; 73(12):1533-40. PubMed ID: 23290326
[TBL] [Abstract][Full Text] [Related]
26. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
27. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Leucht S; Crippa A; Siafis S; Patel MX; Orsini N; Davis JM
Am J Psychiatry; 2020 Apr; 177(4):342-353. PubMed ID: 31838873
[TBL] [Abstract][Full Text] [Related]
28. Effects of risperidone on affective symptoms in patients with schizophrenia.
Peuskens J; Van Baelen B; De Smedt C; Lemmens P
Int Clin Psychopharmacol; 2000 Nov; 15(6):343-9. PubMed ID: 11110010
[TBL] [Abstract][Full Text] [Related]
29. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone.
Kasper S; Montagnani G; Trespi G; Di Fiorino M
Int Clin Psychopharmacol; 2015 Jan; 30(1):14-22. PubMed ID: 25356632
[TBL] [Abstract][Full Text] [Related]
30. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
31. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
[TBL] [Abstract][Full Text] [Related]
32. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
[TBL] [Abstract][Full Text] [Related]
33. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
Casey DE; Daniel DG; Wassef AA; Tracy KA; Wozniak P; Sommerville KW
Neuropsychopharmacology; 2003 Jan; 28(1):182-92. PubMed ID: 12496955
[TBL] [Abstract][Full Text] [Related]
34. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
35. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
István S; Agoston T; Tamás T; Zoltán J
Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
[TBL] [Abstract][Full Text] [Related]
36. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.
Keefe RS; Young CA; Rock SL; Purdon SE; Gold JM; Breier A;
Schizophr Res; 2006 Jan; 81(1):1-15. PubMed ID: 16202565
[TBL] [Abstract][Full Text] [Related]
37. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
[TBL] [Abstract][Full Text] [Related]
38. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.
Müller-Siecheneder F; Müller MJ; Hillert A; Szegedi A; Wetzel H; Benkert O
J Clin Psychopharmacol; 1998 Apr; 18(2):111-20. PubMed ID: 9555596
[TBL] [Abstract][Full Text] [Related]
39. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
Citrome L
Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
[TBL] [Abstract][Full Text] [Related]
40. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
Sacchetti E; Valsecchi P; Parrinello G;
Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
